Dana-Farber, Beth Israel Deaconess plan to build free-standing inpatient cancer hospital

Swim Across America grants $900,000 toward gene editing innovation

Joseph FraiettaPietro GenoveseSwim Across America, the nonprofit funding innovative clinical trials and patient-centered programs for cancer, awarded $450,000 grants to two of its beneficiaries, Alliance for Cancer Gene Therapy and Dana-Farber Cancer Institute, to support the work of novel gene and base editing techniques used in advanced cancer research, including targeted therapies, immunotherapies, and cellular therapies.

April 25, 2025

Vol.51 No.16

In Brief

Kimberly Stegmaier appointed chair of pediatric oncology at Dana-Farber

Kimberly Stegmaier was named chair of Pediatric Oncology at Dana-Farber Cancer Institute and associate chief of the Division of Hematology/Oncology at Boston Children’s Hospital. Her appointment is effective April 1.

February 21, 2025

Vol.51 No.07

Clinical Roundup

Cancer vaccine shows promise for patients with stage 3 and 4 kidney cancer

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage 3 or 4 clear cell renal cell carcinoma generated a successful anti-cancer immune response after initiation of a personalized cancer vaccine.

February 07, 2025

Vol.51 No.05

Clinical Roundup

DFCI researchers use PET imaging to detect body inflammation

Researchers at Dana-Farber Cancer Institute developed a method to detect inflammation in the body using positron emission tomography imaging. This innovative probe targets CD45, a marker abundantly expressed on all immune cells but absent from other cell types.

January 24, 2025

Vol.51 No.03

In Brief

Elizabeth Mittendorf elected ASCO president for 2026-2027 term

The American Society of Clinical Oncology elected Elizabeth A. Mittendorf to lead as its president beginning in June 2026. Mittendorf, a long-time ASCO member and volunteer, will take office as president-elect immediately following the ASCO Annual Business Meeting in Chicago on June 2.

January 17, 2025

Vol.51 No.02

In Brief

Dana-Farber launches Center for RAS Therapeutics to target the RAS oncogene in cancer

Dana-Farber Cancer Institute will launch the Center for RAS Therapeutics, a multidisciplinary initiative to advance scientific investigation, translational research, and clinical care approaches for patients with RAS-driven cancers.

January 10, 2025

Vol.51 No.01

Dana-Farber, Beth Israel Deaconess plan to build free-standing inpatient cancer hospital

YOU MAY BE INTERESTED IN

Swim Across America grants $900,000 toward gene editing innovation

Kimberly Stegmaier appointed chair of pediatric oncology at Dana-Farber

Cancer vaccine shows promise for patients with stage 3 and 4 kidney cancer

DFCI researchers use PET imaging to detect body inflammation

Elizabeth Mittendorf elected ASCO president for 2026-2027 term

Dana-Farber launches Center for RAS Therapeutics to target the RAS oncogene in cancer

Renew today!

Subscriber content

Never miss an issue!

Login